Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Cash from Operations (2024 - 2026)

Evommune (EVMN) reported Cash from Operations of 27503000.0 for Q1 2026, down 15.08% year-over-year from 32387001.58 in Q1 2025, and down 64.7% on a QoQ basis from 16699000.0 in Q4 2025.

Evommune (EVMN) has 3 years of Cash from Operations data on file, last reported at 27503000.0 in Q1 2026.

  • Quarterly Cash from Operations fell 15.08% year-over-year to 27503000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 86613000.0 (changed N/A YoY) and the FY2025 annual result came in at 76441000.0, down 31.35% from the prior year.
  • Cash from Operations slipped to 27503000.0 in Q1 2026 per EVMN's latest filing, from 16699000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 16699000.0 in Q4 2025 and bottomed at 27503000.0 in Q1 2026.
  • The 3-year median for Cash from Operations is 21205500.0 (2024), against an average of 21653250.0.
  • The widest annual swing landed in 2025, when Cash from Operations climbed 9.79%; it then slipped 15.08% in 2026.
  • Tracing EVMN's Cash from Operations over 3 years: stood at 18512000.0 in 2024, then grew by 9.79% to 16699000.0 in 2025, then slumped by 64.7% to 27503000.0 in 2026.
  • Per Business Quant, the three latest EVMN Cash from Operations figures stand at 27503000.0 (Q1 2026), 16699000.0 (Q4 2025), and 23899000.0 (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -1.67 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -12.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -2.49 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.43 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.08 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 70.50 Mn
10 Evommune 744.11 Mn 532.65 Mn - -27.50 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -27.50 Mn
Mar 31, 2026 -27.50 Mn
Dec 31, 2025 -16.70 Mn
Dec 31, 2025 -16.70 Mn
Mar 31, 2025 -23.90 Mn
Mar 31, 2025 -23.90 Mn
Dec 31, 2024 -18.51 Mn
Dec 31, 2024 -18.51 Mn